Posters
« Back
Survival outcomes following stereotactic radiosurgery for patients with brain metastases: a single centre experience
EP30711
Poster Title: Survival outcomes following stereotactic radiosurgery for patients with brain metastases: a single centre experience
Submitted on 07 Nov 2019
Author(s): Martin R Brewer, Chiara Reverberi, Jessica Yanwube, Helen Taylor, Philippa Sturt, Michaela James, Mostafa El-Haddad, Antonia Creak, Nicola Rosenfelder, Frank Saran, Liam Welsh
Affiliations: The Royal Marsden NHS Foundation Trust
This poster was presented at BIR Annual Congress 2019
Poster Views: 10
View poster »


Poster Information
Abstract: Introduction
Stereotactic Radiosurgery (SRS) for the treatment of brain metastases is a specialist service commissioned by NHS England in May 2016 (1). Patients deemed eligible for SRS should have an expected survival of at least 6 months. This retrospective study evaluates overall survival (OS) in patients with brain metastases treated with SRS at The Royal Marsden Hospital and assesses survival according to tumour sub-type.

Methods
All patients meeting service eligibility criteria (1) treated between May 2016 and September 2018 were included in this analysis. Patients having treatment to a surgical cavity were excluded. Treatment was delivered on a CyberKnife VSI platform according to departmental protocols. OS was calculated for the entire patient cohort and three most common primary tumour types and their molecular subtypes known to affect systemic treatment options.

Results
386 patients were treated within the analysis period with a median follow-up of 9.9 months (range 1-35 months). Median OS for the entire cohort was 15.2 months. OS rates at 6, 12 and 24 months was 72.5%, 55.1% and 38.4% respectively. Median OS for breast (n=90), lung (n=162), and melanoma (n=49) primaries were 19.7, 14.8, and 15.3 months respectively. Subgroup analyses of molecular characteristics demonstrate favourable OS in patients harbouring mutations.

Conclusions
Median OS was >12 months but is <6 months in >25% of patients and this requires further analysis. Primary tumour histology and molecular subtype is likely to significantly affect OS. Sequencing and timing of SRS with newer targeted systemic therapies requires further assessment in prospective studies.
Summary: A single centre experience and outcomes of treating brain metastases with stereotactic radiosurgeryReferences: 1. NHS England (2013) Clinical Commissioning Policy: Stereotactic Radiosurgery / Radiotherapy for Cerebral Metastases https://www.england.nhs.uk/d05/Report abuse »
Creative Commons

Related Posters


Etiological diagnostics of cardiomyopathies in the cardiology unit of the HUEH internal medicine department during the period from 8 January 2014 to 14 June 2014
*Axler JEAN PAUL; **Lesly Ed. ARCHER; *Raema Mimrod JEAN; *Gerald VERNELUS; *Rodolph MALEBRANCHE

Medical Student: Move over Stem Cells – Exosomes are Here! What are Exosomes & their role in Regenerative Medicine?
Amartej Singh Deol MD4 & Advisor: Shivinder S. Deol MD

Resident: NONHEALING ULCER THE NEED TO LOOK FURTHER
Briand Bounkeu MD; Ravi Shekarappa MD; La Toya Jackson DO, FAAFP; Chinedu Ivonye MD, FACP; Cristal Kudiwu MD

Striving for Equity in Surgical, Anesthesia, and Obstetric Research in Haiti: A Multi-Partner, International Research Training Collaboration
Dr. Jean Alouidor*, Dr. Frédéric Barau Déjean*, Dr. Louis-Franck Télémaque, Dr. Ronald Eveillard, Dr. Laëlle Mangurat, Dr. Isaac Martineau, Dr. Chartelin Jean Isaac, Dr. Darlène Rochelin Paultre, Carine Réveil Jean-Baptiste, Dr. Lucile Louis Riché, Dr. Jordan Pyda, Rolvix Patterson III, Dr. Blake Alkire, Dr. Eunice Dérivois-Mérisier (*Co-First Authors)

Projektstatus: Entwicklung einer konsensbasierten Therapieempfehlung für die PADOVAN-METHODE® in der Neurorehabilitation
Eisenmeier, Dimitri1; Ostermann, Thomas1; Vogel, Hannah1; Fetz, Katharina1